LabGenius through to OneStart Finals

LabGenius are finalists in the OneStart competition! The LabGenius antibody discovery platform has been selected in the top 2% of 750 applicants worldwide. Through the OneStart process, the team have established a number of early stage partnerships in antibody engineering. We would like to thank our mentors for their time, advice and wisdom; we are hugely grateful for all their support throughout this process.

 

LabGenius selected for OneStart Semi Finals

LabGenius have been announced as semifinalists in the OneStart competition, the world’s largest life sciences and healthcare startup accelerator, founded by Oxbridge Biotech Roundtable and SR One. Teams are competing to win a non-dilutive £100,000 1st place prize. The LabGenius team are pitching an antibody discovery platform, based around our sequence design and library synthesis capabilities. Already, the competition has proved to be an invaluable opportunity to build relationships with pharmaceutical companies, allowing us to initiate discussions around a feasibility study of the discovery platform.

 

LabGenius awards academics $10,000 of DNA in its inaugural library design competition

LabGenius' synthetic DNA library synthesis technology enables researchers to rapidly engineer novel biological products and systems. The company's inaugural library design competition challenged academics to identify innovative applications for this technology.  

The competition results, which were announced at the SynBioBeta SF 2015 conference, saw research groups from Denmark and Germany named as joint winners. 

Mette-Marie Wendelboe Nielsen and the 2015 iGEM SDU Denmark team plan to use their LabGenius library to search for novel peptide aptamers.

Carlos G. Acevedo-Rocha, from the Max Planck Institute for Terrestrial Microbiology in Marburg, Germany will use his library to re-engineer the cytochrome P45 protein.

LabGenius identified as a key player in gene synthesis market

LabGenius were recognised as a key player in the DNA synthesis market, at the recent SynBioBeta Activate! conference in Boston.

LabGenius' CEO, James Field, and Principal Scientist Harry Rickerby were in attendance. James presented on the development of LabGenius' synthetic DNA library technology the impact that it is having on both industrial and academic research.